—
C+
C+ The full Closelook — membership. Open the C+ overview

Spyre Therapeutics Inc. (SYRE) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Spyre Therapeutics Inc.

SYRE in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Spyre Therapeutics is a clinical-stage biotechnology company that develops antibody treatments for inflammatory bowel disease and rheumatic conditions. Its lead candidate targets the a4ß7 integrin for ulcerative colitis and Crohn's disease, alongside separate antibodies aimed at TL1A and IL-23, some combined into dual-target programmes. It was previously named Aeglea BioTherapeutics before adopting its current name in 2023, and is based in Waltham, Massachusetts.
Where it sits in the stack
Spyre sits outside the diary's AI build-out coverage; it belongs to the healthcare sector, within the biotechnology industry grouping of our wider universe, and carries no Rubin or Halo seat.
Who it is priced against
The diary holds no peer group for this name; it operates in the same clinical field as other immunology-focused developers such as AbbVie, which the market commonly names as a comparison in that therapeutic area.
Why Closelook tracks it
It carries a Closelook score, but only one module has been scored so far, so the score is still being built. It holds no index seat in the diary and has not yet been quoted in any edition.
What the diary watches
The diary watches how phase-2 results for its lead antibody candidates come through, since the shares have already moved well above their 200-day level even as the analyst price target was recently trimmed.

Spyre Therapeutics Inc. (SYRE) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for SYRE, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 3 analyst actions on the wire · latest: price target by Wedbush, 2026-08-26

The Street on this name

Analyst actions and the latest print for SYRE from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Wedbush — target 123 from 130 Target cut to $123 from $130 (+29.2% to spot) 2026-08-26
  • Price target BTIG — target 121 from 132 Target cut to $121 from $132 (+12.7% to spot) 2026-08-26
  • Price target Deutsche Bank — target 127 from 135 Target cut to $127 from $135 (+18.3% to spot) 2026-08-26

3 actions on the analyst wire since 2026-08-13: 3 target changes. Analyst wire → · Earnings wire →

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against SYRE on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

How it trades on rate days beta 0.81 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How SYRE has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.81 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Spyre Therapeutics Inc. moved 0.81% on average · correlation 0.11 · higher than 78% of US names
  • Beta, last 3 months 1.42 more rate-sensitive lately than over the year
  • On the 10 worst bond days +0.12% on average against −0.76% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −4.13% TLT −1.58% that day 2026-09-23

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 65/100 · S&P 500 fund at 68, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-23
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +9.3% over 20 sessions. Factor regime → 2026-09-23
  • Sovereign pressure Index 0.60 · up 0.32 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-23

FAQ · from the current data · as of 2026-09-24

Quick answers

What is Spyre Therapeutics Inc. (SYRE)?

Spyre Therapeutics Inc. trades as SYRE on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-24.

Is SYRE in a Closelook index?

Not currently — Spyre Therapeutics Inc. is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-24.

Where does SYRE trade against its moving averages?

Pullback inside an uptrend stack: Trades -9.6% vs the 50-day and +34.1% vs the 200-day average, 20% below the 52-week high and +483.5% off the 52-week low. Computed from daily closes. As of 2026-09-23 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Spyre Therapeutics Inc. do?

Spyre Therapeutics is a clinical-stage biotechnology company that develops antibody treatments for inflammatory bowel disease and rheumatic conditions. Its lead candidate targets the a4ß7 integrin for ulcerative colitis and Crohn's disease, alongside separate antibodies aimed at TL1A and IL-23, some combined into dual-target programmes. It was previously named Aeglea BioTherapeutics before adopting its current name in 2023, and is based in Waltham, Massachusetts. The diary holds no peer group for this name; it operates in the same clinical field as other immunology-focused developers such as AbbVie, which the market commonly names as a comparison in that therapeutic area.

Where does Spyre Therapeutics Inc. sit in the AI build-out?

Spyre sits outside the diary's AI build-out coverage; it belongs to the healthcare sector, within the biotechnology industry grouping of our wider universe, and carries no Rubin or Halo seat. It carries a Closelook score, but only one module has been scored so far, so the score is still being built. It holds no index seat in the diary and has not yet been quoted in any edition.

How does Spyre Therapeutics Inc. trade when bond yields rise?

Over the past year Spyre Therapeutics Inc. had a beta of 0.81 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 78% of US names. On the 10 sessions in which long bonds fell most it moved +0.12% on average, against −0.76% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What has Wall Street done on Spyre Therapeutics Inc. recently?

The most recent analyst action on Spyre Therapeutics Inc. on the Closelook wire is a price target by Wedbush on 2026-08-26 (target 123 from 130). 3 actions on the analyst wire since 2026-08-13: 3 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for SYRE, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.